| Doctors hail new era for cancer screening as major research shows effectiveness of Galleri test Doctors  have told health services to prepare for a new era of cancer screening  after a study found a simple blood test could spot multiple cancer types  in patients before they develop clear symptoms.
 The Pathfinder study  offered the blood test to more than 6,600 adults aged 50 and over, and  detected dozens of new cases of disease. Many cancers were at an early  stage and nearly three-quarters were forms not routinely screened for. It is the first time results from the Galleri test, which looks for cancer DNA in the blood, have been returned to patients and their doctors, to guide cancer investigations and any necessary treatment. The Galleri test has been described as a potential "gamechanger" by NHS England, which is due to report results from a major trial  involving 165,000 people next year. Doctors hope the test will save  lives by detecting cancer early enough for surgery and treatment to be  more effective, but the technology is still in development.
 "I  think what's exciting about this new paradigm and concept is that many  of these were cancers for which we do not have any standard screening,"  Dr Deb Schrag, a senior researcher on the study at the Memorial Sloan  Kettering Cancer Center in New York, told the European Society for Medical Oncology meeting in Paris on Sunday. In  the Pathfinder study, 6,621 adults aged 50 and over were offered the  Galleri blood test. For 6,529 volunteers, the test was negative, but it  flagged a potential cancer in 92. Further tests  confirmed solid tumours or blood cancer in 35 people, or 1.4% of the  study group. The test spotted two cancers in a woman who had breast and  endometrial tumours. Beyond spotting the  presence of disease, the test predicts where the cancer is, allowing  doctors to fast-track the follow-up work needed to locate and confirm a  cancer. "The signal of origin was very helpful in directing the type of  work-up," said Schrag. "When the blood test was positive, it typically  took under three months to get the work-ups completed." The  test identified 19 solid tumours in tissues such as the breast, liver,  lung and colon, but it also spotted ovarian and pancreatic cancers,  which are typically detected at a late stage and have poor survival rates. The  remaining cases were blood cancers. Out of the 36 cancers detected in  total, 14 were early stage and 26 were forms of the disease not  routinely screened for.
 Further analyses found  the blood test was negative for 99.1% of those who were cancer-free,  meaning only a small proportion of healthy people wrongly received a  positive result. About 38% of those who had a positive test turned out  to have cancer. Schrag said that the test  not yet ready for population-wide screening and that people must continue with standard cancer screening  while the technology is improved. "But this still suggests a glimpse of  what the future may hold with a really very different approach to  cancer screening," she said. Fabrice  André, the director of research at Gustave Roussy cancer centre in  Villejuif, France, said: "Within the next five years, we will need more  doctors, surgeons and nurses, together with more diagnostic and  treatment infrastructure, to care for the rising number of people who  will be identified by multi-cancer early detection tests." Naser  Turabi, the director of evidence and implementation at Cancer Research  UK, said: "Blood tests for multiple types of cancer used to belong in  the realm of science fiction, but now they are an area of cancer  research that is showing promise for patients. "Research  like this is crucial for making progress against late-stage cancers and  giving more patients the chance of a good outcome. The Pathfinder trial  results give us a better understanding of how frequently cancer is  found by this blood test in people who haven't been previously  diagnosed. "But we will need data from larger  studies to fully assess this test and other similar tests in  development, especially to understand whether people actually survive  for longer after their cancer is picked up." | 
No comments:
Post a Comment